A phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of intravenous efzofitimod in patients with pulmonary sarcoidosis

About this Study

This study will assess the efficacy of efzofitimod in patients with pulmonary sarcoidosis, assess the safety and tolerability of efzofitimod in patients with pulmonary sarcoidosis, and explore the utility of serum biomarkers in the evaluation of interventions to treat pulmonary sarcoidosis.

Sponsor Protocol ID:aTyr1923-C-001
IRB Number:2023-61
Actively Enrolling
Interventional
Phase 3
September 13, 2023
Eligibility Criteria
18 years old
75 years old
Both Male and Female
No
No
No
Categories Click category to view its trials.
Lungs/Breathing
Participating Locations
University Hospital - UMMC
Contact Information
Contact Name: Jennifer Lowery
Phone Number: 601-496-7814
Email: jslowery@umc.edu
Principal Investigator:Andrew, Wilhelm, DO
How to participate in our Clinical Trials